Choose a body system to explore the published research, evidence and limitations.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, not a peptide. Mouse and cell studies report metabolic effects, but they do not establish effective human weight loss, improved longevity or a validated safety profile for commercial products.
AOD-9604 is a modified growth-hormone fragment investigated for obesity. Animal fat-metabolism findings did not translate into convincing human weight-loss efficacy, and a large clinical program was discontinued. It is not an FDA-approved obesity medicine or full-length growth-hormone replacement.
Abaloparatide is a bone-forming prescription medicine for adults with osteoporosis at high fracture risk. It activates the parathyroid hormone type 1 receptor. Its strongest fracture-prevention evidence is in postmenopausal women; the indication in men is supported by increased bone mineral density.
Acetyl hexapeptide-8 is a topical cosmetic peptide commonly associated with Argireline. Small controlled studies suggest an effect on wrinkle appearance, but they do not establish equivalence to injected botulinum toxin. Delivery through intact skin and the finished formulation remain important limitations.
Acetyl octapeptide-3, commonly associated with SNAP-8, is a cosmetic ingredient marketed for expression-line appearance. Direct evidence for the isolated ingredient is limited. Studies of multi-ingredient microneedle patches cannot establish the effect of ordinary topical SNAP-8 products on their own.
Acetyl tetrapeptide-5 is a cosmetic ingredient associated with the original Eyeseryl eye-contour products. Independent evidence isolating its contribution to puffiness or dark circles is sparse. A study of an injected multi-component product cannot validate a topical cream or the peptide alone.
Afamelanotide is the active ingredient in a prescription implant used for adults with erythropoietic protoporphyria. Melanotan I is a historical name for the molecule. The approved medical use is distinct from unapproved products marketed for cosmetic tanning.
Albiglutide is a long-acting GLP-1 medicine previously marketed for type 2 diabetes. It has randomized cardiovascular-outcome evidence, but its historical approvals must be distinguished from current availability: the European authorization was withdrawn after commercial discontinuation.
Amycretin, now also known as zenagamtide, is an investigational peptide combining GLP-1 and amylin-related receptor activity in one molecule. Oral and injectable programs have shown metabolic effects in human trials, but their formulations, endpoints and evidence maturity differ.
Angiotensin II is a natural blood-pressure-regulating hormone and an approved intravenous vasopressor for adults with septic or other distributive shock. It can raise pressure when conventional vasopressors are insufficient. The pivotal evidence primarily concerns blood-pressure response, while thrombosis is an important safety concern.
Apraglutide is an investigational GLP-2 analog for short bowel syndrome with intestinal failure. A phase 3 trial showed reduced parenteral-support volume, but regulatory development continues, including an additional confirmatory study; it is not an approved substitute for teduglutide.
Aviptadil is synthetic vasoactive intestinal peptide, a signaling molecule with vascular and immune effects. Major trials did not establish benefit for severe COVID-19 respiratory failure. A combination with phentolamine is licensed for erectile dysfunction in some countries, a different formulation and indication from investigational lung treatment.